Pancreatic Cancer Research

ResearcherConsejo Superior de Investigaciones CientíficasActive in the last 2 years

Pilar Navarro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4314-4584; OpenAlex author ID A5039737999. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: none · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 16

  1. Lateral flow immunoassay detection of soluble AXL for pancreatic ductal adenocarcinoma diagnosis. Co-author DOI 10.1016/j.talanta.2026.129973↗
  2. PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. Last author DOI 10.1126/sciadv.adu8849↗
  3. Quantitative characterization of the 3D self-organization of PDAC tumor spheroids reveals cell type and matrix dependence through advanced microscopy analysis. Co-author DOI 10.1063/5.0242490↗
  4. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Last author DOI 10.1073/pnas.2424051122↗
  5. Hallmarks of pancreatic cancer: spotlight on TAM receptors. Last author DOI 10.1016/j.ebiom.2024.105278↗
  6. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. Co-author DOI 10.1016/j.ebiom.2021.103797↗
  7. Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in… Co-author DOI 10.3390/cancers14246133↗
  8. The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer. Last author DOI 10.3390/cells9030689↗
  9. Knockdown of α2,3-Sialyltransferases Impairs Pancreatic Cancer Cell Migration, Invasion and E-selectin-Dependent Adhesion. Co-author DOI 10.3390/ijms21176239↗
  10. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Last author DOI 10.1073/pnas.1722434115↗
  11. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Last author DOI 10.18632/oncotarget.26034↗
  12. Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Last author DOI 10.3390/cancers10010006↗
  13. The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Last author DOI 10.18632/oncotarget.10199↗
  14. Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. Last author DOI 10.1002/path.4384↗
  15. Targeting Galectin-1 in pancreatic cancer: immune surveillance on guard. First author DOI 10.4161/21624011.2014.952201↗
  16. Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc. Last author DOI 10.1007/s12029-011-9258-0↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Neus Martínez‐Bosch · 15 shared papers, 2014–2026 · strength 2.34
  2. Noemí Manero‐Rupérez · 5 shared papers, 2020–2026 · strength 0.86
  3. Núria Vázquez-Bellón · 3 shared papers, 2024–2026 · strength 0.84
  4. Pablo Garcı́a de Frutos · 3 shared papers, 2022–2026 · strength 0.74
  5. Pedro Enrique Guerrero · 5 shared papers, 2016–2025 · strength 0.68
  6. Laura Visa · 4 shared papers, 2018–2026 · strength 0.65
  7. Carmen E. Guerra · 4 shared papers, 2014–2026 · strength 0.47
  8. Judith Vinaixa · 4 shared papers, 2016–2025 · strength 0.46
  9. Soraya Hernández-Hatibi · 1 shared paper, 2025 · strength 0.30
  10. José Manuel García‐Aznar · 1 shared paper, 2025 · strength 0.30
  11. J.‐Pablo Salvador · 1 shared paper, 2026 · strength 0.30
  12. Martín E. Fernández-Zapico · 2 shared papers, 2018–2025 · strength 0.27
  13. Laura Miró · 2 shared papers, 2020–2022 · strength 0.26
  14. Esther Llop · 2 shared papers, 2020–2022 · strength 0.26
  15. Rosa Peracaula · 2 shared papers, 2020–2022 · strength 0.26
  16. Renzo Emanuel Vera · 1 shared paper, 2025 · strength 0.20
  17. Patricia Santofimia‐Castaño · 1 shared paper, 2025 · strength 0.20
  18. David R Pease · 1 shared paper, 2025 · strength 0.20
  19. Juan Iovanna · 1 shared paper, 2025 · strength 0.20
  20. Alfredo Carrato · 2 shared papers, 2018–2022 · strength 0.20
  21. Julie Earl · 2 shared papers, 2018–2022 · strength 0.20
  22. Carlos A. Orozco · 3 shared papers, 2016–2018 · strength 0.19
  23. Meritxell Gironella · 1 shared paper, 2022 · strength 0.13
  24. Κωνσταντίνος Κωνσταντόπουλος · 1 shared paper, 2020 · strength 0.11
  25. Bin Sheng Wong · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.